CDEK
← All drugs Report issue

allogeneic stem cells

Cell therapyexperimental

Clinical trial activity

89 trials · 112 clinical orgs · 0 marketing orgs

Phase 1
28
Phase 2
63
Phase 3
11
Phase 4
2

Earliest trial started Dec 1, 1992 (NCT00186810)

Timeline

1990s

  1. Jan 1, 1992

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 1999

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetTissue restoration

    tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • allogeneic blood stem cell
  • allogeneic human stem cell
  • allogeneic peripheral blood stem cells
  • allogeneic stem cell
  • allogeneic stem cells
  • allogenic stem cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06974968Phase 2May 25, 2028Government of China, Sun Yat-Sen University
NCT07118319Phase 1Sep 15, 2025Government of China
NCT06976229Phase 1Jul 2, 2025Government of China, Sun Yat-Sen University
NCT06724237Phase 3Dec 1, 2024Eastern Cooperative Oncology Group, ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
NCT06280092Early Phase 1 (Phase 1)Oct 31, 2024Mayo Clinic
NCT06471946Phase 1/Phase 2 (Phase 2)Oct 1, 2024Government of China
NCT06512545N/AJul 1, 2024Peking University
NCT06512519N/AJul 1, 2024Anhui Medical University, Fujian Medical University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Hacettepe University, Huazhong University of Science and Technology, Jiao Tong University, Nanjing Medical University, Peking University, People's Liberation Army of China, Shandong Provincial Hospital, Shengjing Hospital, Soochow University, Southern Medical University, Xinjiang Medical University, Zhejiang University, Zhengzhou University
NCT06059391Phase 2Dec 25, 2023City of Hope National Medical Center, National Cancer Institute (NCI)
NCT05675319Phase 3Mar 3, 2023Gemeinsamer Bundesausschuss, Staburo GmbH, University of Hamburg
NCT05157958Phase 2Jan 1, 2022Anterogen Co., Ltd.
NCT04684979Phase 2Nov 30, 2021Baptist Health
NCT04628026Phase 3Oct 30, 2021HOVON - Dutch Haemato-Oncology Association, University of Ulm
NCT04497805Phase 2Aug 31, 2020Anterogen Co., Ltd.
NCT04179760Phase 1/Phase 2 (Phase 2)Jan 31, 2020Inha University, SCM Lifescience Co., LTD.
NCT04232241Phase 2Nov 14, 2019CTC Bio, Inc., DKMS Stiftung Leben Spenden, University of Hamburg
NCT04801563N/ASep 20, 2019University of Perugia
NCT04189419Phase 1/Phase 2 (Phase 2)Aug 12, 2019SCM Lifescience Co., LTD., Soon Chun Hyang University
NCT03910452Early Phase 1 (Phase 1)Jul 5, 2019National Institute of Allergy and Infectious Diseases (NIAID)
NCT03717545N/AMar 1, 2018Peking University
Showing 20 of 89 trials
Page 1 / 5

Organizations

Research & Development (112)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of Texas at HoustonAcademic/Hospital131321998
National Cancer Institute (NCI)Government8332001
St. Jude Children's HospitalAcademic/Hospital5531992
GenzymeFor profit4112006
Government of ChinaGovernment4422024
Harvard UniversityAcademic/Hospital4322004
Peking UniversityAcademic/Hospital4322014
Cornell UniversityAcademic/Hospital3322001
Northwestern UniversityAcademic/Hospital3322003
PETHEMA FoundationAcademic/Hospital3332000
Sun Yat-Sen UniversityAcademic/Hospital3022014
University of BarcelonaAcademic/Hospital3032000
AmgenFor profit2012005
Anterogen Co., Ltd.For profit2212020
CelgeneFor profit2022009
ClinAssess GmbHFor profit2022009
Columbia UniversityAcademic/Hospital2222004
Fujian Medical UniversityAcademic/Hospital2122017
Julius-Maximilians UniversityAcademic/Hospital2222009
National Institute of Allergy and Infectious Diseases (NIAID)Government2212015
112 organizations
Page 1 / 6